RHYTHM PHARMACEUTICALS, INC. Operating Lease, Payments, Use
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Operating Lease, Payments, Use of $636.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePaymentsUse · last filed 2024-11-06
- RHYTHM PHARMACEUTICALS, INC. operating lease, payments, use for the quarter ending 2024-09-30 was $215.00K, a 2.38% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. operating lease, payments, use for the quarter ending 2023-12-31 was $211.00K.
- RHYTHM PHARMACEUTICALS, INC. operating lease, payments, use for the quarter ending 2023-09-30 was $210.00K.
- RHYTHM PHARMACEUTICALS, INC. operating lease, payments, use for the quarter ending 2020-12-31 was $199.00K, a 2.05% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. operating lease, payments, use for fiscal 2023 was $834.00K, a 1.96% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. operating lease, payments, use for fiscal 2022 was $818.00K, a 2.00% increase from fiscal 2021.
- RHYTHM PHARMACEUTICALS, INC. operating lease, payments, use for fiscal 2021 was $802.00K, a 2.04% increase from fiscal 2020.
- RHYTHM PHARMACEUTICALS, INC. operating lease, payments, use for fiscal 2020 was $786.00K, a 84.94% increase from fiscal 2019.
| Period end | Operating Lease, Payments, Use 3 month | Operating Lease, Payments, Use 6 month | Operating Lease, Payments, Use 9 month | Operating Lease, Payments, Use 12 month |
|---|---|---|---|---|
| 2024-09-30 | $215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $636.00K 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | $421.00K 10-Q · filed 2024-08-06 | |||
| 2023-12-31 | $211.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $421.00K derived: sum of 2 quarters · filed 2024-11-06 | $834.00K 10-K · filed 2024-02-29 | |
| 2023-09-30 | $210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $623.00K 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $413.00K 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $818.00K 10-K · filed 2024-02-29 | |||
| 2021-12-31 | $802.00K 10-K · filed 2024-02-29 | |||
| 2020-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $396.00K derived: sum of 2 quarters · filed 2023-03-01 | $591.00K derived: sum of 3 quarters · filed 2023-03-01 | $786.00K 10-K · filed 2023-03-01 |
| 2020-09-30 | $197.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $392.00K derived: sum of 2 quarters · filed 2020-11-02 | $587.00K 10-Q · filed 2020-11-02 | $782.00K derived: sum of 4 quarters · filed 2020-11-02 |
| 2020-06-30 | $195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $390.00K 10-Q · filed 2020-08-03 | $585.00K derived: sum of 3 quarters · filed 2020-08-03 | $715.00K derived: sum of 4 quarters · filed 2020-08-03 |
| 2020-03-31 | $195.00K 10-Q · filed 2020-05-04 | $390.00K derived: sum of 2 quarters · filed 2020-05-04 | $520.00K derived: sum of 3 quarters · filed 2020-05-04 | $545.00K derived: sum of 4 quarters · filed 2020-05-04 |
| 2019-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $325.00K derived: sum of 2 quarters · filed 2020-03-02 | $350.00K derived: sum of 3 quarters · filed 2020-03-02 | $425.00K 10-K · filed 2020-03-02 |
| 2019-09-30 | $130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | $155.00K derived: sum of 2 quarters · filed 2019-11-01 | $230.00K 10-Q · filed 2019-11-01 | |
| 2019-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $100.00K 10-Q · filed 2019-07-29 | ||
| 2019-03-31 | $75.00K 10-Q · filed 2019-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |